With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML||Children's Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD||Reach Grants||2017||Wisconsin|
|Targeting Novel Pediatric-Specific FLT3 Mutations||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD||Reach Grants||2015||Washington|
|Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD||Reach Grants||2018||Washington|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|
|Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma||Baylor College of Medicine / Cliona Rooney, PhD||Reach Grants||2013||Texas|
|B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers||University of Texas Southwestern Medical Center / James Amatruda, MD, PhD||Reach Grants||2013||Texas|
|Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor||Baylor College of Medicine / William Decker, PhD||Reach Grants||2013||Texas|
|Targeting PLK1 as a Common Mechanism in Ph-like ALL||University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD||Reach Grants||2016||Texas|
|Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors||Children's Hospital of Philadelphia / Garrett Brodeur, MD||Reach Grants||2019||Pennsylvania|
|Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition||Children's Hospital of Philadelphia / Yael Mossé, MD||Reach Grants||2013||Pennsylvania|